Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables: 2015-2024

Historic Receivables for Capricor Therapeutics (CAPR) over the last 1 years, with Dec 2024 value amounting to $20.4 million.

  • Capricor Therapeutics' Receivables fell 0.02% to $20.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $45.9 million, marking a year-over-year increase of 66.34%. This contributed to the annual value of $20.4 million for FY2024, which is 0.02% down from last year.
  • Per Capricor Therapeutics' latest filing, its Receivables stood at $20.4 million for Q4 2024, which was down 0.02% from $20.4 million recorded in Q4 2023.
  • In the past 5 years, Capricor Therapeutics' Receivables registered a high of $20.4 million during Q4 2023, and its lowest value of $20.4 million during Q4 2024.
  • In the last 2 years, Capricor Therapeutics' Receivables had a median value of $20.4 million in 2023 and averaged $20.4 million.
  • Data for Capricor Therapeutics' Receivables shows a maximum YoY fell of 0.02% (in 2024) over the last 5 years.
  • Capricor Therapeutics' Receivables (Quarterly) stood at $20.4 million in 2023, then dropped by 0.02% to $20.4 million in 2024.
  • Its Receivables stands at $20.4 million for Q4 2024, versus $20.4 million for Q4 2023 and $2.6 million for Q4 2015.